Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04106609
Other study ID # Maple Tree Exercise
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 23, 2019
Est. completion date October 28, 2021

Study information

Verified date June 2024
Source Kettering Health Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To test the effect of an individualized exercise oncology program on healthcare utilization, 30-day hospital readmission, pain, and cancer treatment tolerance.


Recruitment information / eligibility

Status Completed
Enrollment 251
Est. completion date October 28, 2021
Est. primary completion date October 28, 2021
Accepts healthy volunteers No
Gender Female
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - Female; determined from electronic medical record - Initial stage 0, 1 or 2 breast cancer diagnosis within the past 12 weeks determined from electronic medical record - Age 30-80; determined from electronic medical record - Physician clearance to participate in exercise Exclusion Criteria: - Participation in supervised physical exercise within 6 months prior to study enrollment - Currently pregnant or planning to become pregnant - Non-English speaking - Unable to make own medical decisions and/or to follow verbal instructions

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Supervised, individualized exercise oncology program
The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
Current standard of care
Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.

Locations

Country Name City State
United States Maple Tree Cancer Alliance Dayton Ohio

Sponsors (1)

Lead Sponsor Collaborator
Karen Wonders

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Missed Fractions Total number of missed fractions, determined by electronic medical record 12 weeks
Primary Numbers of Breaks in Cancer Treatment Defined as missing 3 or more fractions due to patient condition, determined by electronic medical record 12 weeks
Primary Cost of Emergency Room Visits Medical expenditure and utilization, for each time a patient utilized an emergency room visit for the purpose of managing health problems in addition to the planned cancer care, determined by electronic medical record. 12 weeks
Primary Encounters Number of inpatient and outpatient hospital encounters, determined by electronic medical record 12 weeks
Primary Cost of Total Unplanned Expenditures Number of hospital readmissions for the same presenting issue, determined by electronic medical record 12 weeks
Primary Cost of Hospital Inpatient Care Hospital length of stay, in days, if applicable. Determined by electronic medical record. 12 weeks
Primary Cancer Treatment Adherence Percentage of patient adherence to their cancer treatment, determined by electronic medical record 12 weeks
Primary Cancer Treatment Symptom Management Medications Number of the different types of medications taken by patients for symptom management during their cancer treatment. Determined by electronic medical record. 12 weeks
Primary Cancer Treatment Related Side Effects Total number of cancer treatment related side effects 12 weeks
Primary Patient Rated Pain Score The Short Form-36 survey was used to measure pain. A high score defines a more favorable health state. Each item is scored on a 0 to 100 range, with the lowest and highest possible scores being 0 and 100, respectively. 12 weeks, measured at the start of their exercise program during their initial assessment and at the 12-week follow-up re-assessment.
Primary Cancer TreatmentTtolerance Measured by the Eastern Cooperative Oncology Group (ECOG) performance status score. Scale is from 0 to 5, with 0 being high functioning and no restriction and 5 being dead. 12 weeks - ECOG performance status measurements were recorded at baseline and at the 12-week follow up appointment.
Primary Quality of Life Measure: Utilizing McGill Quality of Life Survey and FACT-B Questionnaire McGill Quality of Life Survey:
Physical Wellbeing (questions 1-4) - minimum score is 0, maximum score is 40. A higher score would be good and lower score would be bad.
Social Wellbeing (questions 12, 14-16) - minimum score is 0, maximum score is 40. A higher score would be good and lower score would be bad.
Emotional Wellbeing(questions 5-7, 13) - minimum score is 0 and maximum score is 40. A higher score would be bad and a lower score would be good Functional wellbeing (questions 8-11) - minimum score is 0, maximum score is 40. A higher score would be good and lower score would be bad.
FACT-BREAST Survey:
Minimum score is 0 and maximum is 148; 0 is not at all and 4 is very much, "good" or "bad" varies depending on the question; overall a higher score is good and a lower score is bad
Baseline was at the time of enrollment and follow up was after 12-weeks.
Secondary Adherence Rate Exercise session adherence rate among the Exercise Group, collected from the Maple Tree Cancer Alliance participant records. Exercise session adherence rate was measured by dividing the total number of sessions scheduled by the total number of exercise sessions actually attended by the exercise group. 12 weeks
Secondary Percentage of Participants Who Completed the Study (Attrition Rate) Exercise program attrition rate among the Exercise Group, collected from the Maple Tree Cancer Alliance participant records. Attrition was determined by calculating the percent of participants who completed the study by the total number of participants who started the study. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A